Oral bisphosphonates. A review of clinical use in patients with bone metastases

Cancer

Volumn 88, Issue 1, 2000, Pages 6-14

  Major, Pierre P ^a   Lipton, Allan ^b   Berenson, James ^c   Hortobagyi, Gabriel ^d  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Bisphosphonates; Bone; Metastases; Trials

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; WY 47766; ZOLEDRONIC ACID;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EYE DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; MEDICAL LITERATURE; METABOLIC BONE DISEASE; MULTIPLE MYELOMA; PEMPHIGUS; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ALENDRONATE; BIOLOGICAL AVAILABILITY; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CALCIUM; CLODRONIC ACID; DIPHOSPHONATES; DOUBLE-BLIND METHOD; ETIDRONIC ACID; HUMANS; IMIDAZOLES; MALE; MULTIPLE MYELOMA; PROSTATIC NEOPLASMS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0033972908     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D     Document Type: Article

References (76)

1. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973;11:69-280.
2. Fleisch H. Bisphosphonates - history and experimental basis. Bone 1987;8(Suppl 1):523-8.
3. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Mineral 1986;1:27-39.
4. Fleisch H. Bisphosphonates in bone disease - from the laboratory to the patient. ed. 2. Canforth, England: Parthenon, 1995:38-56.
5. Body JJ. Clinical research update - zoledronate. Cancer 1997;80(Suppl 8):1699-701.
6. Medical Economics. Product labeling, Didronel®. Physicians' desk reference. ed 52. Montvale, NJ: Medical Economics, 1998:2317-8.
7. Medical Economics. Product labeling, Aredia®. Physicians' desk reference. ed 52. Montvale, NJ: Medical Economics, 1998:1824-9.
8. Medical Economics. Product labeling, Fosamax®. Physicians' desk reference, ed 52. Montvale, NJ: Medical Economics, 1998:1657-61.
9. Medical Economics. Product labeling, Skelid®. Physicians' desk reference. ed 52. Montvale, NJ: Medical Economics, 1998:2590-2.
10. Ralston SH, Patel U, Fraser WD, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989;2:1180-2.
11. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134-42.
12. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995;38:851-8.
13. Daley-Yates PD, Dowell DJ, Pongchaidecha M, et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991;49:433-5.
14. Fleisch H. Disphosphonates. Calcif Tissue Int 1997;27:91-4.
15. Pentikainen PJ, Elomaa I, Nurmi AK, Karkkainen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 1989;27(5):222-8.
16. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate - an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-2.
17. DeGroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;35: 1016-20.
18. Kanis JA, Gray RE. Long term follow-up observations on treatment on Paget's disease of bone. Clin Orthop 1987;217: 99-125.
19. Robertson AG, Reed NS, Ralston SH, Effect of oral clodronate on metastatic bone pain: a double blind, placebo-controlled study. J Clin Oncol 1995;13:2427-30.
20. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
21. Siris ES, Sherman WH, Baquiran DC, et al. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 1980;302:310-5.
22. < MDP) on skeletal lesions in multiple myeloma. Met Bone Dis Rel Res 1982;4:163-8.
23. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;240:1049-52.
24. Laakso M, Lahtinen R, Virkunnen P, et al. Subgroup and cost benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 87:725-9.
25. McCloskey EV, MacLennan ICM, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998;100:317-25.
26. Spector TDF, McCloskey EV, Mootswang I, et al. The epidemiology of vertebral fractures in the general population. The Clingford Study. J Bone Mineral Res 1999; (Suppl 6):227-79.
27. Heim MS, Clemens MR, Queisser W, et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 1995;15:439-48.
28. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clinic Oncol 1991;9:1397-402.
29. Boyce BF, Fogelman I, Ralston S, et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984;1:821-4.
30. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
31. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998;101:280-6.
32. Elomaa I, Blomqvist C, Grohn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983;1:146-9.
33. Elomaa I, Blomqvist C, Porkka L, et al. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 1988;42:111-6.
34. Siris ES, Hyman GA, Canfield RE. Effects dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983;74:401-6.
35. Dodwell DJ, Howell A, Ford J. Reduction in calcium excretion in women with breast cancer bone metastases using the oral bisphosphonate pamidronate. Br J Cancer 1990;60:123-5.
36. Coleman RE, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer 1992;65: 766-8.
37. Paterson AHG, Powles TJ, Kanis JA, et al. Double blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
38. Kanis, JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
39. Van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996;32A:450-4.
40. Windeler J, Lange S. Events per person year - a dubious concept. Br Med J 1995;39:454-6.
41. Major PP, Cook RJ, Tozer R, Hirte H. Bisphosphonates for bone metastases in breast cancer patients: trial design issues and evaluation of published studies. Curr Oncol 1998; 5:181-7.
42. Cook RJ, Lawless JF, Nadeau C. Robust tests for treatment comparisons based on recurrent event responses. Biometrics 1996;52:557-71.
43. Rizzoli R, Forni M, Schaad MA, et al. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 1996;18:531-7.
44. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
45. Burckhardt P. Ibandronate in oncology. Cancer 1997; 80(Suppl 1):1696-8.
46. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491-8.
47. van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet 1987;2:983-5.
48. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
49. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997;80(Suppl 8):1668-73.
50. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind placebo-controlled study. J Urol 1989;141:85-7.
51. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain - a controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992;24:159-66.
52. Kylmala T, Tammela T, Risteli L, et al. Evaluation of the effects of oral clodronate on skeletal metastases with Type I collagen metabolities. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993;291:821-5.
53. Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985;134:1152-4.
54. Kylmala T, Tammela TLJ, Lindholm, et al. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chirurg Gynecol 1994;83:316-9.
55. Cresswell SM, English PJ, Hall RR, et al. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995;76:360-5.
56. O'Rouke N, McCloskey E, Houghton F, et al. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995;13:929-34.
57. Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945-82.
58. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcemia, and Paget's disease of bone. Drugs Aging 1998;12:149-68.
59. Fleisch H. Bisphosphonates in bone disease - from the laboratory to the patient. ed 3. New York, NY: Parthenon, 1997:152-9.
60. Coleman RE, Purohit OP, Black E, et al. Double blind, randomised, placebo-controlled, dose finding study of oral Ibandronate in patients with metastatic bone disease. Ann Oncol 1999;10:311-6.
61. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
62. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333: 1437-43.
63. DeVries HR, Bijvoet OLM. Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Neth J Med 1974;17:281-98.
64. Jowsey J, Riggs BL, Kelly PJ, et al. The treatment of osteoporosis with disodium ethane-1-hydorxy-1,1-diphosphonate. J Lab Clin Med 1971;78:574-85.
65. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289-318.
66. Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993;342:1459-60.
67. Berenson JR. Bisphosphonates in multiple myeloma. Cancer 1997;80:1661-7.
68. Bounameaux HM, Schifferli, J, Montani JP, et al. Renal failure associated with intravenous diphosphonate [letter]. Lancet 1993;1:471.
69. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphonate administration. Calcif Tissue Int 1987;41:326-31.
70. Papapoulos SE, Harinck JIJ, Bijvoet OLM, et al. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolities in normocalcaemic and hypercalcaemic patients treated with APD. Bone Mineral 1986;1:69-78.
71. Marcarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Opthalmol 1994;118:220-4.
72. Roux C, Listrat V, Villette B, et al. Long-lasting dermatological lesions after tiludronate therapy. Calcif Tissue Int 1992; 50:378-80.
73. Diel IJ, Marschner N, Kindler M, Lang O, et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. ASCO 1998;18:488.
74. Diel IJ, Solomayer EF, Costa SD, Golla C, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;399:357-63.
75. Powles TJ, Paterson AHG, Nevantaus A, Legault S, et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. ASCO 1998;17:468.
76. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. No reduction of bone metastases with adjuvant clodronate treatment in node positive breast cancer patients. ASCO 1999;18:489.